Stock Track | Becton Dickinson Soars 5.03% Intraday on Positive Analyst Ratings Including Barclays Reinstatement

Stock Track02-12

Becton Dickinson's stock surged 5.03% during intraday trading on Wednesday, reflecting strong investor confidence in the medical technology company.

The price movement appears to be driven by a series of positive analyst actions. Barclays reinstated coverage of Becton Dickinson with an Overweight rating and set a price target of $202 per share. Jefferies maintained its Buy rating on the stock with a $190 price target, while Citigroup also maintained its Buy rating despite adjusting its price target downward from $232 to $198.

These analyst actions collectively signal continued confidence in Becton Dickinson's prospects, with multiple firms reiterating positive ratings that likely contributed to the stock's significant intraday gain.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1139505996?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-12 00:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1139505996","market":"us","top_or_hot":-1,"title":"Stock Track | Becton Dickinson Soars 5.03% Intraday on Positive Analyst Ratings Including Barclays Reinstatement","media":"Stock Track","content":"<p>Becton Dickinson's stock surged 5.03% during intraday trading on Wednesday, reflecting strong investor confidence in the medical technology company.</p><p>The price movement appears to be driven by a series of positive analyst actions. Barclays reinstated coverage of Becton Dickinson with an Overweight rating and set a price target of $202 per share. Jefferies maintained its Buy rating on the stock with a $190 price target, while Citigroup also maintained its Buy rating despite adjusting its price target downward from $232 to $198.</p><p>These analyst actions collectively signal continued confidence in Becton Dickinson's prospects, with multiple firms reiterating positive ratings that likely contributed to the stock's significant intraday gain.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Becton Dickinson Soars 5.03% Intraday on Positive Analyst Ratings Including Barclays Reinstatement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Becton Dickinson Soars 5.03% Intraday on Positive Analyst Ratings Including Barclays Reinstatement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-12 00:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Becton Dickinson's stock surged 5.03% during intraday trading on Wednesday, reflecting strong investor confidence in the medical technology company.</p><p>The price movement appears to be driven by a series of positive analyst actions. Barclays reinstated coverage of Becton Dickinson with an Overweight rating and set a price target of $202 per share. Jefferies maintained its Buy rating on the stock with a $190 price target, while Citigroup also maintained its Buy rating despite adjusting its price target downward from $232 to $198.</p><p>These analyst actions collectively signal continued confidence in Becton Dickinson's prospects, with multiple firms reiterating positive ratings that likely contributed to the stock's significant intraday gain.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BDX","symbol_name":"碧迪医疗","start_time":0,"source_url":"","article_id":"1139505996","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1139505996","pubTimestamp":1770826639,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Becton Dickinson's stock surged 5.03% during intraday trading on Wednesday, reflecting strong investor confidence in the medical technology company.The price movement appears to be driven by a series...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BDX":"碧迪医疗"},"translate_title":"个股追踪|巴克莱复职等分析师正面评级Becton Dickinson盘中飙升5.03%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BDX":1},"content_text":"Becton Dickinson's stock surged 5.03% during intraday trading on Wednesday, reflecting strong investor confidence in the medical technology company.The price movement appears to be driven by a series of positive analyst actions. Barclays reinstated coverage of Becton Dickinson with an Overweight rating and set a price target of $202 per share. Jefferies maintained its Buy rating on the stock with a $190 price target, while Citigroup also maintained its Buy rating despite adjusting its price target downward from $232 to $198.These analyst actions collectively signal continued confidence in Becton Dickinson's prospects, with multiple firms reiterating positive ratings that likely contributed to the stock's significant intraday gain.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1139505996","isCrawlerRequest":true}